Tavapadon no Parkinson: resultados dos estudos fase 3

The results of phase 3 studies for a new Parkinson's drug, Tavapadon, have just been released. But the question is: 👉 Does it really change the game? In this video, I explain clearly and practically: ⚙️ How Tavapadon works in the brain 🧬 What makes it different from current dopamine agonists 📊 What phase 3 studies have shown 👥 For which patients it may be most useful ⚠️ And what are the possible side effects 💡 Tavapadon is a selective dopamine agonist (D1/D5), which opens up a new possibility in treatment: 👉 stimulating dopaminergic pathways in a more physiological way 👉 potentially with fewer classic side effects But… as always in medicine: ❗ we need to interpret the results with caution ❗ understand the ideal patient profile ❗ and see how this translates into real clinical practice 🎯 The main point: We are entering a new phase in Parkinson's treatment — more targeted, more modern and potentially smarter. 📢 If you want to understand the new therapies that are emerging: 👉 Subscribe to the channel 💬 Tell me here: Have you ever heard of Tavapadon? Share this video:    • Tavapadon no Parkinson: resultados dos est...   ------------------ 🔴 SUBSCRIBE to the channel:    / @dr.rubenscury   ------------------ ✅Other channels: ➡️ Instagram: https://bit.ly/InstagramDrRubensCury ➡️ Website: https://rubenscury.com.br/ ------------------ Dr. Rubens Gisbert Cury Neurologist. PhD in Neurology from USP (University of São Paulo). Post-doctoral studies in Neurology at USP and the University of Grenoble, France. Associate Professor at USP (University of São Paulo). CRM/SP: 131445 RQE: 64840 ------------------ LEGAL NOTICE: The information contained in the videos is not intended to replace consultation with a medical professional or serve as a recommendation for any treatment plan. In accordance with the Medical Code of Ethics, the videos are for educational purposes only.